Armata Secures Additional $2.5M DoD Funding to Advance AP-SA02 Phase 3 Readiness
ARMP•Armata Pharmaceuticals received an additional $2.5 million in non-dilutive DoD funding, raising total awards to $28.7 million for AP-SA02 development. The funds will support key activities to achieve Phase 3 readiness for the adjunct treatment of complicated Staphylococcus aureus bacteremia.
1. Additional DoD Award Funding
Armata received an additional $2.5 million from the Department of Defense via MTEC and the Naval Advanced Medical Development program, bringing cumulative non-dilutive support for AP-SA02 to $28.7 million to date.
2. Phase 3 Readiness Activities
The latest award will finance critical tasks—including manufacturing scale-up, protocol finalization and regulatory submissions—to enable initiation of a Phase 3 superiority study of intravenous AP-SA02 in complicated Staphylococcus aureus bacteremia in the second half of 2026.
3. AP-SA02 Clinical Profile
AP-SA02 is a fixed multi-phage cocktail targeting MSSA and MRSA bacteremia that has received QIDP and Fast Track designations and demonstrated positive safety and efficacy signals in a Phase 1b/2a diSArm trial.
4. Strategic and Clinical Implications
Non-dilutive Department of Defense funding underscores confidence in phage therapy’s potential to address antimicrobial resistance, minimizes equity dilution and supports development for both military and civilian patient populations.
